Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 250 results for "Mk 5172"

Merck Announces Results from Studies Evaluating Investigational Hepatitis C Treatments, MK-5172 and MK-8742, in Treatment-Nave Patients with Genotype 1 Infection
Scottrade

SAFETY AND EFFICACY OF THE ALL-ORAL REGIMEN OF MK-5172 / MK-87...

EASL - The International Liver Congress 2014 49th Annual Meeting of the European Association for the Study of the Liver London, United Kingdom April 9-13 Reported by Jules Levin Presented at the 49th Annual Meeting of the European Association ... National AIDS Treatment Advocacy Project, 5 days ago
[x]  

3 images for "Mk 5172"

Scottrade, 1 week ago
Scottrade, 1 month ago
Scottrade, 5 months ago

SVR AND SAFETY OF LOWER DOSES OF MK-5172 25 MG AND 50 MG DAILY FOR 12 WEEKS IN HCV GENOTYPE (G)1 TREATMENT-NAIVE NON-CIRRHOTIC PATIENTS

EASL - The International Liver Congress 2014 49th Annual Meeting of the European Association for the Study of the Liver London, United Kingdom April 9-13 Reported by Jules Levin EASL 2014 April 9-10 London, UK Martin Lagging, Ashley Brown, Ola ...
 National AIDS Treatment Advocacy Project1 week ago Dose-dependent Pharmacokinetics for MK-5172 25 mg, 50 mg, and 100 mg Once Daily for 12 Weeks in HCV Genotype 1 Treatment-nave Non-cirrhotic Patients  National AIDS Treatment Advocacy Project1 week ago

HCV Combo Therapy Demonstrates Antiviral Activity in Hard-to-Cure Patients

MK-5172/MK-8742 shows promise in mid-stage trial Positive results have been reported from the ongoing C-WORTHy study, a phase II clinical trial evaluating the efficacy and safety of an all-oral, once-daily regimen combining MK-5172, an ...
 P&T Community1 week ago

Current Awards 3/19/2014 C5482

Current Awards 4/09/2014 DWSP 2014-12 WC0798 Furnish and Deliver One 91) 4-Wheel Drive Loader/Backhoe With Multipurpose Bucket $96,908.25 Island Equipment Inc. dba American Machinery 4/09/2014 14-05A WC0796 Omaopio Tank ...
 Maui County2 days ago
Motley Fool

If This Biotech Drops Much Further I'm Going to Buy It!

We've seen a little bit of a relief rally over the past couple of days in the overall market with the start of earnings season giving investors hope that the U.S. economy and corporations can keep motoring higher. On the all, though, it's been a ...
 Motley Fool2 days ago

Will Merck & Co. Inc Unseat Biotech's Hottest Drug?

No drug has hit the market running like Gilead Sciences ' ( NASDAQ: GILD ) freshly approved oral hepatitis C drug Sovaldi. In a market that analysts estimate could be worth up to $20 billion, Sovaldi's made a huge impact in gaining regulatory ...
 Motley Fool2 days ago Merck Hepatitis C combo pill impresses in Phase II  Seeking Alpha1 week ago Merck Data Show Potent Rival to Gilead's Hepatitis C Pill  Bloomberg1 week ago Merck Data Show Potent Drug Rival to Gilead's Hepatitis C Pill  Washington Post1 week ago

How Much Has Merck Shaken Up the Hepatitis C Race?

Even the wildest Gilead ( NASDAQ: GILD ) bulls seemed to acknowledge that the company was not going to grab and hold 100% share of the hepatitis C (HCV) market. Now the question seems to be shifting to just how much share rivals like AbbVie ( ...
 Motley Fool4 days ago

Hard-to-Cure Patients May Benefit from Merck's HCV Drug

Merck ( MRK ) presented interim data from an ongoing phase II study on its once-daily, all-oral hepatitis C virus (:HCV) combination regimen MK-5172 (a NS3/4A protease inhibitor) and MK-8742 (a NS5A replication complex inhibitor). The additional ...
 Yahoo! Finance5 days ago Merck Up on Encouraging HCV Data  Yahoo! Finance1 week ago Merck Up on Encouraging HCV Data - Analyst Blog  Benzinga.com1 week ago
[x]  

C-WORTHy: Novel therapies show promise in patients with cirrhosis, previous null responders

LONDON — Response rates to combination therapy with two novel Merck compounds with or without ribavirin were higher than 90% across a cohort of traditionally difficult-to-treat patients with hepatitis C virus, according to new data presented here.
 Orthopedics Today4 days ago

EASL Coverage: 6 phase 3 studies; Simeprevir+Sofosbuvir Update; HIV Coinfection: 2 studies reported

EASL: - (04/14/14) EASL: - (04/14/14) from Jules: Over 10,000 attended this EASL conference organizers reported, in London at the ExCel Center in the Canary Wharf section of London. I have been attending EASL every year since 1998 when the ...
 National AIDS Treatment Advocacy Project4 days ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - Mk 5172
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less